Clinical Trial Update: An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial evaluating YM155 in combination with docetaxel in advanced hormone-refractory prostate cancer and other solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Solid Tumors

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• YM155 (Sepantronium bromide)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Prostate Cancer, Tumors | Phase 1, Phase 2 | Status: COMPLETED